2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart …
JA Joglar, MK Chung, AL Armbruster, EJ Benjamin… - Circulation, 2024 - Am Heart Assoc
AIM The “2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial
Fibrillation” provides recommendations to guide clinicians in the treatment of patients with …
Fibrillation” provides recommendations to guide clinicians in the treatment of patients with …
[HTML][HTML] Haemostatic alterations and management of haemostasis in patients with cirrhosis
T Lisman, SH Caldwell, NM Intagliata - Journal of Hepatology, 2022 - Elsevier
Patients with cirrhosis frequently acquire complex changes in their haemostatic system
including a decreased platelet count and decreased levels of various haemostatic proteins …
including a decreased platelet count and decreased levels of various haemostatic proteins …
2021 Focused update of the 2017 consensus guidelines of the Asia Pacific Heart Rhythm Society (APHRS) on stroke prevention in atrial fibrillation
The consensus of the Asia Pacific Heart Rhythm Society (APHRS) on stroke prevention in
atrial fibrillation (AF) has been published in 2017 which provided useful clinical guidance for …
atrial fibrillation (AF) has been published in 2017 which provided useful clinical guidance for …
Direct oral anticoagulants in patients with atrial fibrillation and liver disease
Background: Advanced liver disease is known to increase the risk for bleeding and affects
the hepatic clearance and metabolism of drugs. Subjects with active liver disease were …
the hepatic clearance and metabolism of drugs. Subjects with active liver disease were …
Effectiveness and safety of four direct oral anticoagulants in Asian patients with nonvalvular atrial fibrillation
YH Chan, HF Lee, LC See, HT Tu, TF Chao, YH Yeh… - Chest, 2019 - Elsevier
Background Whether four direct oral anticoagulants (DOACs) are superior to warfarin in
Asian patients with nonvalvular atrial fibrillation (NVAF) remains unclear. Methods This …
Asian patients with nonvalvular atrial fibrillation (NVAF) remains unclear. Methods This …
Comparative effectiveness and safety of direct oral anticoagulants and warfarin in patients with atrial fibrillation and chronic liver disease: a nationwide cohort study
Background: The benefit-risk profile of direct oral anticoagulants (DOACs) compared with
warfarin, and between DOACs in patients with atrial fibrillation (AF) and chronic liver disease …
warfarin, and between DOACs in patients with atrial fibrillation (AF) and chronic liver disease …
[HTML][HTML] Direct oral anticoagulants in patients with liver disease in the era of non-alcoholic fatty liver disease global epidemic: a narrative review
S Ballestri, M Capitelli, MC Fontana, D Arioli… - Advances in …, 2020 - Springer
Atrial fibrillation (AF) and venous thromboembolism (VTE) are highly prevalent and relevant
healthcare issues. Direct oral anticoagulants (DOACs) are now the first-choice for …
healthcare issues. Direct oral anticoagulants (DOACs) are now the first-choice for …
[HTML][HTML] The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl …
AWC Ling, CC Chan, SW Chen, YW Kao… - Cardiovascular …, 2020 - Springer
Background Sodium glucose cotransporter 2 inhibitor (SGLT2i) reduces the risk of hard
cardiovascular endpoints in type 2 diabetes mellitus (T2DM) patients with/without …
cardiovascular endpoints in type 2 diabetes mellitus (T2DM) patients with/without …
Rates of bleeding and discontinuation of direct oral anticoagulants in patients with decompensated cirrhosis
JF Mort, JPE Davis, G Mahoro, MJ Stotts… - Clinical …, 2021 - Elsevier
Background & Aims Studies of the effects of direct oral anticoagulants (DOACs) in patients
with cirrhosis have been limited by their small sample size, inclusion of patients with well …
with cirrhosis have been limited by their small sample size, inclusion of patients with well …
New-onset atrial fibrillation in patients with type 2 diabetes treated with novel glucose-lowering therapies
FC Hsiao, KC Yen, TF Chao, SW Chen… - The Journal of …, 2022 - academic.oup.com
Context Whether sodium-glucose cotransporter 2 inhibitors (SGLT2is) are associated with
lower risk of new-onset atrial fibrillation (AF) compared with glucagon-like peptide-1 receptor …
lower risk of new-onset atrial fibrillation (AF) compared with glucagon-like peptide-1 receptor …